Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabine + Cisplatin (GEM/CIS) remains the standard first-line treatment for advanced stage CCA. However, this drug combination yields only a modest o...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasopporn, Sunisa, Suppramote, Orawan, Ponvilawan, Ben, Jamyuang, Chanette, Chanthercrob, Jantappapa, Chaiboonchoe, Amphun, More-Krong, Pimkanya, Kongsri, Kamonchanok, Suntiparpluacha, Monthira, Chanwat, Rawisak, Korphaisarn, Krittiya, Okada, Seiji, Sampattavanich, Somponnat, Jirawatnotai, Siwanon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748615/
https://www.ncbi.nlm.nih.gov/pubmed/36531039
http://dx.doi.org/10.3389/fonc.2022.1021632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748615/
https://www.ncbi.nlm.nih.gov/pubmed/36531039
http://dx.doi.org/10.3389/fonc.2022.1021632

Ejemplares similares